StockData
argenx SE logo

argenx SE (ARGX) stock

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$941.25−6.27 (-0.66%)

Close on Nov 18, 2026Market cap –P/E 48.1Yield –

argenx net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2025 it was $1.29B, up 55.1% from the year before. The highest annual figure on record is $1.29B in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.29B+55.1%
FY2024Dec 31, 2024$833.04M–
FY2023Dec 31, 2023-$295.05M–
FY2022Dec 31, 2022-$709.59M–
FY2021Dec 31, 2021-$408.27M–
FY2020Dec 31, 2020-$608.46M–

More argenx figures

See a number that looks wrong?